Study to Compare Oral PF-06651600, PF-06700841 and Placebo in Subjects With Moderate to Severe Ulcerative Colitis
- Conditions
- Ulcerative Colitis
- Interventions
- Registration Number
- NCT02958865
- Lead Sponsor
- Pfizer
- Brief Summary
The purpose of this study is to determine whether PF-06651600 and PF-06700841 are effective in treatment of moderate to severe ulcerative colitis.
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- COMPLETED
- Sex
- All
- Target Recruitment
- 319
- Diagnosis of ulcerative colitis for greater than/equal to 3 months.
- Moderate to severe active ulcerative colitis
- Inadequate response to, loss of response to, or intolerance to at least one conventional therapy for UC.
- Pregnant or breastfeeding
- Clinical findings suggestive of Crohn's Disease
- History of bowel surgery within 6 months
Study & Design
- Study Type
- INTERVENTIONAL
- Study Design
- PARALLEL
- Arm && Interventions
Group Intervention Description PF-06700841 Drug Dose Level 3 PF-06700841 or Placebo Delivered orally for 8 weeks. PF-06651600 Drug Dose Level 1 PF-06651600 or Placebo Delivered orally for 8 weeks PF-06651600 Drug Dose Level 2 PF-06651600 or Placebo Delivered orally for 8 weeks PF-06700841 Placebo PF-06700841 or Placebo Delivered orally for 8 weeks. PF-06651600 Drug Dose Level 4 PF-06651600 Delivered orally for 24 weeks. PF-06651600 Drug Dose Level 3 PF-06651600 or Placebo Delivered orally for 8 weeks. PF-06651600 Placebo PF-06651600 or Placebo Delivered orally for 8 weeks. PF-06700841 Drug Dose Level 4 PF-06700841 Delivered orally for 24 weeks. PF-06700841 Drug Dose Level 1 PF-06700841 or Placebo Delivered orally for 8 weeks PF-06700841 Drug Dose Level 2 PF-06700841 or Placebo Delivered orally for 8 weeks.
- Primary Outcome Measures
Name Time Method Total Mayo Score at Week 8 (Induction Period) Week 8 The Mayo score is a tool designed to measure disease activity for ulcerative colitis. The Mayo scoring system ranges from 0 to 12 points and consists of 4 subscores, which are stool frequency, rectal bleeding, findings on endoscopy and physician's global assessment. Each subscore graded 0 to 3 with the higher score indicates more severe disease activity and lower score denotes improvement of disease activity as measured by the total Mayo score.
- Secondary Outcome Measures
Name Time Method Number of Participants With Laboratory Test Abnormalities-urinalysis (Chronic Period) Week 8 to Week 32 The number of participants with a laboratory abnormality meeting specified criteria while on study treatment or during lag time are reported here. Baseline is defined as the last measurement prior to receiving study treatment. The list of urinalysis test parameters were as follows:pH, glucose (qual), protein (qual), blood (qual), ketones, nitrites, leukocyte esterase, microscopy, and spot urine albumin/creatinine ratio. The criteria of laboratory abnormality is defined as one of the following conditions was met: 1)associated with accompanying symptoms;2)Test result requires additional diagnostic testing or medical/surgical intervention;3)Test result leads to a change in study dosing (outside of any protocol specified dose adjustments) or discontinuation from the study, significant additional concomitant drug treatment, or other therapy;4)Test result is considered to be an AE by the investigator or sponsor.
Number of Participants With Adverse Events (AEs), Serious Adverse Events (SAEs) and Discontinuation Due to AEs (All-causalities) (Induction Period) From Day 1 up to Week 8 An AE was an untoward medical occurrence in a participant who received study treatment without regard to possibility of causal relationship. An SAE was an AE resulting in any of the following outcomes: death, life-threatening experience, initial or prolonged inpatient hospitalization, persistent or significant disability/incapacity, congenital anomaly/birth defect. Treatment-emergent AEs were those with initial onset or that worsen in severity after the first dose of study medication. All AEs mentioned below are treatment-emergent AEs.
Percentage of Participants Achieving Symptomatic Remission Based on Total Mayo Score at Week 8 (Induction Period) Week 8 The Mayo Score is a tool designed to measure disease activity for ulcerative colitis. The Mayo scoring system ranges from 0 to 12 points and consists of 4 subscores, which are stool frequency, rectal bleeding, findings on endoscopy and physician's global assessment. Each subscore graded 0 to 3 with the higher score indicating more severe disease activity. Symptomatic remission was defined as total Mayo score of 2 points or lower, with no individual subscore exceeding 1 point, and both rectal bleeding and stool frequency subscores of 0.
Percentage of Participants Achieving Deep Remission Based on Total Mayo Score at Week 8 (Induction Period) Week 8 The Mayo Score is a tool designed to measure disease activity for ulcerative colitis. The Mayo scoring system ranges from 0 to 12 points and consists of 4 subscores, which are stool frequency, rectal bleeding, findings on endoscopy and physician's global assessment. Each subscore graded 0 to 3 with the higher score indicating more severe disease activity. Deep remission was defined as total Mayo score of 2 points or lower, with no individual subscore exceeding 1 point and a zero on both endoscopic and rectal bleeding subscore.
Change From Baseline in Total Mayo Score at Week 8 (Induction Period) Baseline, Week 8 The Mayo Score is a tool designed to measure disease activity for ulcerative colitis. The Mayo scoring system ranges from 0 to 12 points and consists of 4 subscores, which are stool frequency, rectal bleeding, findings on endoscopy and physician's global assessment. Each subscore graded 0 to 3 with the higher score indicating more severe disease activity.
Change From Baseline in IBDQ Total Score at Weeks 4 and 8 (Induction Period) Baseline, Weeks 4 and 8 IBDQ is a psychometrically validated PRO instrument for measuring the disease specific quality of life in participants with IBD. The IBDQ is comprised of 32 items, which are grouped into 4 dimensions: bowel function, emotional status, systemic symptoms and social function. The 4 domains are scored as follows: Bowel symptoms: 10 to 70; Systemic symptoms: 5 to 35.; Emotional function: 12 to 84; Social function: 5 to 35. The total IBDQ score ranges from 32 to 224. For the total score and each domain, a higher score indicates better quality of life. Baseline value is defined as the last non-missing measurement collected prior to or on Day 1.
Number of Participants With AEs, SAEs and Discontinuation Due to AEs (Chronic Period) From Week 8 up to Week 32 An AE was an untoward medical occurrence in a participant who received study treatment without regard to possibility of causal relationship. An SAE was an AE resulting in any of the following outcomes: death, life-threatening experience, initial or prolonged inpatient hospitalization, persistent or significant disability/incapacity, congenital anomaly/birth defect. Treatment-emergent AEs were those with initial onset or that worsen in severity after the first dose of study medication. All AEs mentioned below are treatment-emergent AEs.
Number of Participants With Abnormal ECG Findings (Chronic Period) Week 8 to Week 32 The number of participants with abnormal ECG findings during the chronic period (from Week 9 to Week 32) are reported below.
Number of Participants With Serious Infections (Chronic Period) Week 8 to Week 32 Serious infections was defined as any infection (for example, viral, bacterial, and fungal) requiring hospitalization or parenteral antimicrobials.
Number of Participants With Laboratory Test Abnormalities (Induction Period) From Day 1 up to Week 8 The number of participants with a laboratory abnormality meeting the pre-specified criteria defined in the study protocol while on study treatment or during lag time are reported here. Baseline is defined as the last measurement prior to receiving study treatment. Laboratory data included hematology test, serum chemistry test, C-creative protein and viral surveillance. The criteria of laboratory abnormality is defined as one of the following conditions was met: 1)associated with accompanying symptoms;2)Test result requires additional diagnostic testing or medical/surgical intervention;3)Test result leads to a change in study dosing (outside of any protocol specified dose adjustments) or discontinuation from the study, significant additional concomitant drug treatment, or other therapy;4)Test result is considered to be an AE by the investigator or sponsor.
Number of Participants With Abnormal Vital Signs Data (Induction Period) From screening to Week 8 The vital signs data included the single sitting blood pressure, pulse rate and temperature. The criteria of vital sign abnormality are indicated below.
Percentage of Participants Achieving Clinical Response Based on Total Mayo Score at Week 8 (Induction Period) Week 8 The Mayo Score is a tool designed to measure disease activity for ulcerative colitis. The Mayo scoring system ranges from 0 to 12 points and consists of 4 subscores, which are stool frequency, rectal bleeding, findings on endoscopy and physician's global assessment. Each subscore graded 0 to 3 with the higher score indicating more severe disease activity. Clinical response was defined as decrease from baseline in total Mayo score of at least 3 points and at least 30%, with an accompanying decrease in the subscore for rectal bleeding of at least 1 point or absolute subscore for rectal bleeding of 0 or 1.
Percentage of Participants Achieving Endoscopic Remission Based on Total Mayo Score at Week 8 (Induction Period) Week 8 The Mayo Score is a tool designed to measure disease activity for ulcerative colitis. The Mayo scoring system ranges from 0 to 12 points and consists of 4 subscores, which are stool frequency, rectal bleeding, findings on endoscopy and physician's global assessment. Each subscore graded 0 to 3 with the higher score indicating more severe disease activity. Endoscopic remission was defined as endoscopic subscore of 0.
Partial Mayo Score and Change From Baseline at Weeks 2, 4 and 8 (Induction Period) Baseline, Weeks 2, 4 and 8 The Mayo Score is a tool designed to measure disease activity for ulcerative colitis. The Mayo scoring system ranges from 0 to 12 points and consists of 4 subscores, which are stool frequency, rectal bleeding, findings on endoscopy and physician's global assessment. Each subscore graded 0 to 3 with the higher score indicating more severe disease activity. The partial Mayo score does not incorporate the endoscopy score and the partial Mayo score ranges from 0 to 9.
Inflammatory Bowel Disease Questionnaire (IBDQ) Domain Score and Total Score at Weeks 4 and 8 (Induction Period) Week 4 and Week 8 IBDQ is a psychometrically validated patient reported outcome (PRO) instrument for measuring the disease specific quality of life in participants with inflammatory bowel disease (IBD). The IBDQ is comprised of 32 items, which are grouped into 4 dimensions: bowel function, emotional status, systemic symptoms and social function. The 4 domains are scored as follows: Bowel symptoms: 10 to 70; Systemic symptoms: 5 to 35.; Emotional function: 12 to 84; Social function: 5 to 35. The total IBDQ score ranges from 32 to 224. For the total score and each domain, a higher score indicates better quality of life.
Number of Participants With Laboratory Test Abnormalities (Chronic Period) From Week 8 to Week 32 The number of participants with a laboratory abnormality meeting the pre-specified criteria defined in the study protocol while on study treatment or during lag time are reported here. Baseline is defined as the last measurement prior to receiving study treatment. Laboratory data included hematology test, serum chemistry test, C-creative protein and viral surveillance.
Percentage of Participants Achieving Remission Based on Total Mayo Score at Week 32 (Chronic Period) Week 32 The Mayo Score is a tool designed to measure disease activity for ulcerative colitis. The Mayo scoring system ranges from 0 to 12 points and consists of 4 subscores, which are stool frequency, rectal bleeding, findings on endoscopy and physician's global assessment. Each subscore graded 0 to 3 with the higher score indicating more severe disease activity. Clinical remission was defined as total Mayo score of 2 points or lower, with no individual subscore exceeding 1 point and a rectal bleeding subscore of 0.
Percentage of Participants Achieving Improvement in Endoscopic Appearance Based on Mayo Score at Week 32 (Chronic Period) Week 32 The Mayo Score is a tool designed to measure disease activity for ulcerative colitis. The Mayo scoring system ranges from 0 to 12 points and consists of 4 subscores, which are stool frequency, rectal bleeding, findings on endoscopy and physician's global assessment. Each subscore graded 0 to 3 with the higher score indicating more severe disease activity. Improvement in endoscopic appearance was defined at Mayo endoscopic subscore of ≤1.
Number of Participants With Laboratory Test Abnormalities-hematology (Chronic Period) From Week 8 to Week 32 The number of participants with a laboratory abnormality meeting specified criteria while on study treatment or during lag time are reported here. Baseline is defined as the last measurement prior to receiving study treatment. The list of hematology test parameters were as follows: hemoglobin, hematocrit, red blood cell count, platelet count, white blood cell count, total neutrophils (absolute, Abs), eosinophils (Abs), monocytes (Abs), basophils (Abs), lymphocytes (Abs), prothrombin time (PT)/international normalized ratio (INR)/partial thromboplastin time (PTT), and reticulocytes (% and Abs). Percentages are displayed for the laboratory tests having a category with greater or equal to 1 evaluable participant.
Number of Participants With Abnormal Vital Signs Data (Chronic Period) From Week 8 to Week 32 The vital signs data included the single sitting blood pressure, pulse rate and temperature. The criteria of vital sign abnormality are indicated below.
Number of Participants With Laboratory Test Abnormalities-hematology (Induction Period) From Day 1 up to Week 8 The number of participants with a laboratory abnormality meeting specified criteria while on study treatment or during lag time are reported here. Baseline is defined as the last measurement prior to receiving study treatment. The list of hematology test parameters were as follows: hemoglobin, hematocrit, red blood cell count, platelet count, white blood cell count, total neutrophils (absolute, Abs), eosinophils (Abs), monocytes (Abs), basophils (Abs), lymphocytes (Abs), prothrombin time (PT)/international normalized ratio (INR)/partial thromboplastin time (PTT), and reticulocytes (% and Abs). Percentages are displayed for the laboratory tests having a category with greater or equal to 1 evaluable participant.
Number of Participants With Laboratory Test Abnormalities- Urinalysis (Induction Period) From Day 1 up to Week 8 The number of participants with a laboratory abnormality meeting specified criteria while on study treatment or during lag time are reported here. Baseline is defined as the last measurement prior to receiving study treatment. The list of urinalysis test parameters were as follows:pH, glucose (qual), protein (qual), blood (qual), ketones, nitrites, leukocyte esterase, microscopy, and spot urine albumin/creatinine ratio. The criteria of laboratory abnormality is defined as one of the following conditions was met: 1)associated with accompanying symptoms;2)Test result requires additional diagnostic testing or medical/surgical intervention;3)Test result leads to a change in study dosing (outside of any protocol specified dose adjustments) or discontinuation from the study, significant additional concomitant drug treatment, or other therapy;4)Test result is considered to be an AE by the investigator or sponsor.
Number of Participants With Laboratory Test Abnormalities-clinical Chemistry (Chronic Period) Week 8 to Week 32 The number of participants with a laboratory abnormality meeting specified criteria while on study treatment or during lag time are reported here. Baseline is defined as the last measurement prior to receiving study treatment. The list of serum chemistry test parameters were as follows: blood urea nitrogen, creatinine, cystatin C, glucose, calcium, sodium, potassium, gamma glutamyl transferase, chloride, aspartate aminotransferase (AST), alanine aminotransferase (ALT), total bilirubin, direct bilirubin, alkaline phosphatase, uric acid, albumin, total protein, creatine kinase (CK), total cholesterol, triglycerides, high-density lipoproteins (HDL), and low-density lipoprotein (LDL).
Number of Participants With Laboratory Test Abnormalities-clinical Chemistry (Induction Period) From Day 1 up to Week 8 The number of participants with a laboratory abnormality meeting specified criteria while on study treatment or during lag time are reported here. Baseline is defined as the last measurement prior to receiving study treatment. The list of serum chemistry test parameters were as follows: blood urea nitrogen, creatinine, cystatin C, glucose, calcium, sodium, potassium, gamma glutamyl transferase, chloride, aspartate aminotransferase (AST), alanine aminotransferase (ALT), total bilirubin, direct bilirubin, alkaline phosphatase, uric acid, albumin, total protein, creatine kinase (CK), total cholesterol, triglycerides, high-density lipoproteins (HDL), and low-density lipoprotein (LDL)
Number of Participants With Abnormal Electrocardiogram (ECG) Findings (Induction Period) From screening to Week 8 The number of participants with abnormal ECG findings during the induction period (from Day 1 to Week 8) are reported below. The criteria of test abnormality is defined as one of the following conditions was met: 1)associated with accompanying symptoms;2)Test result requires additional diagnostic testing or medical/surgical intervention;3)Test result leads to a change in study dosing (outside of any protocol specified dose adjustments) or discontinuation from the study, significant additional concomitant drug treatment, or other therapy;4)Test result is considered to be an AE by the investigator or sponsor.
Number of Participants With Serious Infections (Induction Period) From Day 1 up to Week 8 Serious infections was defined as any infection (for example, viral, bacterial, and fungal) requiring hospitalization or parenteral antimicrobials including Listeria encephalitis, Pneumonia, Viral infection.
Percentage of Participants Achieving Remission Based on Total Mayo Score at Week 8 (Induction Period) Week 8 The Mayo Score is a tool designed to measure disease activity for ulcerative colitis. The Mayo scoring system ranges from 0 to 12 points and consists of 4 subscores, which are stool frequency, rectal bleeding, findings on endoscopy and physician's global assessment. Each subscore graded 0 to 3 with the higher score indicating more severe disease activity. Clinical remission was defined as total Mayo score of 2 points or lower, with no individual subscore exceeding 1 point and a rectal bleeding subscore of 0.
Percentage of Participants Achieving Improvement in Endoscopic Appearance Based on Total Mayo Score at Week 8 (Induction Period) Week 8 The Mayo Score is a tool designed to measure disease activity for ulcerative colitis. The Mayo scoring system ranges from 0 to 12 points and consists of 4 subscores, which are stool frequency, rectal bleeding, findings on endoscopy and physician's global assessment. Each subscore graded 0 to 3 with the higher score indicating more severe disease activity. Improvement in endoscopic subscore appearance was defined at Mayo endoscopic subscore of ≤1.
Percentage of Participants With IBDQ Total Score Greater Than or Equal to 170 at Weeks 4 and 8 (Induction Period) Week 4 and Week 8 IBDQ is a psychometrically validated PRO instrument for measuring the disease specific quality of life in participants with IBD. The IBDQ is comprised of 32 items, which are grouped into 4 dimensions: bowel function, emotional status, systemic symptoms and social function. The 4 domains are scored as follows: Bowel symptoms: 10 to 70; Systemic symptoms: 5 to 35.; Emotional function: 12 to 84; Social function: 5 to 35. The total IBDQ score ranges from 32 to 224. For the total score and each domain, a higher score indicates better quality of life.
Percentage of Participants With Greater Than or Equal to 16 Points Increase in IBDQ Total Score From Baseline at Weeks 4 and 8 (Induction Period) Baseline, Week 4 and 8 IBDQ is a psychometrically validated PRO instrument for measuring the disease specific quality of life in participants with IBD. The IBDQ is comprised of 32 items, which are grouped into 4 dimensions: bowel function, emotional status, systemic symptoms and social function. The 4 domains are scored as follows: Bowel symptoms: 10 to 70; Systemic symptoms: 5 to 35.; Emotional function: 12 to 84; Social function: 5 to 35. The total IBDQ score ranges from 32 to 224. For the total score and each domain, a higher score indicates better quality of life.
Percentage of Participants With Improvement in IBDQ Bowel Symptom Domain at Weeks 4 and 8 (Induction Period) Week 4 and Week 8 IBDQ is a psychometrically validated PRO instrument for measuring the disease specific quality of life in participants with IBD. The IBDQ is comprised of 32 items, which are grouped into 4 dimensions: bowel function, emotional status, systemic symptoms and social function. The 4 domains are scored as follows: Bowel symptoms: 10 to 70; Systemic symptoms: 5 to 35.; Emotional function: 12 to 84; Social function: 5 to 35. The total IBDQ score ranges from 32 to 224. For the total score and each domain, a higher score indicates better quality of life. The improvement in IBDQ bowel symptom domain was defined as an increase of ≥1.2 points from baseline in average score among bowel symptoms domain (items 1, 5, 9, 13, 17, 20, 22, 24, 26, 29).
Change From Baseline in Euro Quality of Life Questionnaire 5 Dimensions 3 Levels (EQ-5D 3L) Utility Score and EQ-5D Visual Analog Scale (VAS) at Weeks 4 and 8 (Induction Period) Week 4 and Week 8 For EQ-5D 3L, participant rated questionnaire to assess generic health status in two parts: single utility score and visual analog scale. For utility score, participants rated their current health state on 5 dimensions: mobility, self-care, usual activities, pain and discomfort, and anxiety and depression with each dimension having three levels of function: 1 indicates no problem; 2 indicates some problem; 3 indicates extreme problem. Scoring formula developed by EuroQol Group assigns a utility value for each domain in the profile. Score was transformed and results in a total score range of 0.05 to 1.00; higher scores indicating a better health state. The EQ-5D VAS records the respondent's self rated health on a scale from 0 (worst imaginable health state) to 100 (best imaginable health state).
Change From Baseline in Short Form 36 Version 2 (SF-36v2) Acute Mental Component Summary (MCS) Score and Physical Component Summary (PCS) Score at Weeks 4 and 8 (Induction Period) Week 4 and Week 8 The SF-36 version 2 (Acute version) is a 36-item generic health status measure. It measures 8 general health concepts or domains: Physical Functioning (PF), Role-Physical (RP), Bodily Pain (BP), General Health (GH), Vitality (VT), Social Functioning (SF), Role-Emotional (RE), and Mental Health (MH). These 8 domains can also be summarized as physical and mental component scores. The summary component scores, Physical Component Summary (PCS) and Mental Component Summary (MCS), are based on a normalized sum of the 8 scale scores PF, RP, BP, GH, VT, SF, RE, and MH . All domains and summary components are scored such that a higher score indicates a higher functioning or health level. The minimum and maximum scores of the PCS Score are 6.1 and 79.7, respectively. The minimum and maximum scores of the MCS Score are -3.8 and 78.7, respectively.
Total Mayo Score at Week 32 (Chronic Period) Week 32 The Mayo Score is a tool designed to measure disease activity for ulcerative colitis. The Mayo scoring system ranges from 0 to 12 points and consists of 4 subscores, which are stool frequency, rectal bleeding, findings on endoscopy and physician's global assessment. Each subscore graded 0 to 3 with the higher score indicating more severe disease activity.
Trial Locations
- Locations (183)
Dothan Surgery Center
🇺🇸Dothan, Alabama, United States
Gut P.C., dba Digestive Health Specialists of the Southeast
🇺🇸Dothan, Alabama, United States
Southern California Research Institute Medical Group/West Gastroenterology Medical Group/Airport En-
🇺🇸Los Angeles, California, United States
West Coast Endoscopy Center
🇺🇸Clearwater, Florida, United States
University of Miami Hospital and Clinics
🇺🇸Miami, Florida, United States
University of Miami Hospital
🇺🇸Miami, Florida, United States
Southwest Gastroenterology
🇺🇸Oak Lawn, Illinois, United States
Cascades Endoscopy Center
🇺🇸Columbia, Maryland, United States
Parkland Health and Hospital System
🇺🇸Dallas, Texas, United States
UT Southwestern Medical Center - CRU Aston
🇺🇸Dallas, Texas, United States
UT Southwestern Medical Center
🇺🇸Dallas, Texas, United States
Baylor College of Medicine- Baylor Medical Center
🇺🇸Houston, Texas, United States
Baylor St. Luke's Medical Center Endoscopy-McNair Campus
🇺🇸Houston, Texas, United States
Gulf Coast Research Group
🇺🇸Houston, Texas, United States
Verity Research
🇺🇸Fairfax, Virginia, United States
University of Washington
🇺🇸Seattle, Washington, United States
Gastro Center of Maryland
🇺🇸Columbia, Maryland, United States
Vinnytsia Regional Clinical Hospital n.a. M.I.Pyrohov
🇺🇦Vinnytsia, Ukraine
Medical Center "Universal clinic Oberig" of "Kapital" LLC, Gastro center
🇺🇦Kyiv, Ukraine
Municipal Non-Profit Enterprise "Lviv Clinical Emergency Care Hospital"
🇺🇦Lviv, Ukraine
Regional Municipal Institution "Chernivtsi Regional Clinical Hospital", gastroenterology department,
🇺🇦Chernivtsi, Ukraine
KO-MED Centra Kliniczne Pulawy
🇵🇱Pulawy, Poland
KM Management spol. s.r.o.
🇸🇰Nitra, Slovakia
Regional Consultative Polyclinic
🇺🇦Chernivtsi, Ukraine
Bristol Hospital
🇺🇸Bristol, Connecticut, United States
Long Beach Clinical Trials Services Inc.
🇺🇸Long Beach, California, United States
Diabetes and Endocrinology Unit
🇮🇱Tel Aviv, Israel
AOU Sant'Orsola-Malpighi
🇮🇹Bologna, BO, Italy
Shaare Zedek Medical Center
🇮🇱Jerusalem, Israel
Istituto Clinico Humanitas
🇮🇹Rozzano, Milan (MI), Italy
Javorszky Odon Korhaz, Gasztroenterologia
🇭🇺Vac, Hungary
Fakultni nemocnice v Motole
🇨🇿Praha 5, Czechia
ETG Kielce
🇵🇱Kielce, Poland
ENDOSKOPIA Sp. z o. o.
🇵🇱Sopot, Poland
H-T. Centrum Medyczne
🇵🇱Tychy, Poland
IRCCS Saverio De Bellis
🇮🇹Castellana Grotte, Bari, Italy
Severance Hospital, Yonsei University Health System
🇰🇷Seoul, Korea, Republic of
Szent Janos Korhaz es Eszak-budai Egyesitett Korhazak I. Belgyogyaszati Gasztroenterologiai Osztaly
🇭🇺Budapest, Hungary
MHAT Dobrich AD
🇧🇬Dobrich, Bulgaria
SPZOZ Wojewodzki Szpital Zespolony im. Jedrzeja Sniadeckiego w Bialymstoku
🇵🇱Bialystok, Poland
Centrum Zdrowia MDM
🇵🇱Warszawa, Poland
WIP Warsaw IBD Point Profesor Kierkus
🇵🇱Warszawa, Poland
A.O.U. Policlinico G. Martino
🇮🇹Messina, ME, Italy
Semmelweis Egyetem, II. Belgyogyaszati Klinika
🇭🇺Budapest, Hungary
Pannonia Maganorvosi Centrum
🇭🇺Budapest, Hungary
"MHAT-Blagoevgrad" AD
🇧🇬Blagoevgrad, Bulgaria
Kyungpook National University Hospital
🇰🇷Daegu, Korea, Republic of
Clalit Health Services
🇮🇱Bat-Yam, Israel
Clinical Hospital Centre Bezanijska Kosa Clinic for Internal Medicine
🇷🇸Belgrade, Serbia
General Hospital "Djordje Joanovic"
🇷🇸Zrenjanin, Serbia
MUDr. Frantisek Horvath Gastroenterologia
🇸🇰Sahy, Slovakia
Private Enterprise of Private Manufacturing Company "Acinus", Medical and Diagnostic Center
🇺🇦Kropyvnytskyi, Ukraine
Azienda Ospedaliero Universitaria Pisana
🇮🇹Pisa, PI, Italy
Ankara Universitesi Tip Fakultesi, Ibn-i Sina Hastanesi, Ic Hastaliklari Anabilim Dali,
🇹🇷Ankara, Turkey
Hacettepe Universitesi Tip Fakultesi
🇹🇷Ankara, Turkey
Hospital Universitari de Bellvitge
🇪🇸L'Hospitalet de Llobregat, Barcelona, Spain
The Catholic University of Korea, Seoul St. Mary's Hospital
🇰🇷Seoul, Korea, Republic of
Hospital Universitario Fundacion Alcorcon
🇪🇸Alcorcon, Madrid, Spain
Federal State Budgetary Scientific Institution
🇷🇺Novosibirsk, Russian Federation
Lexmedica
🇵🇱Wroclaw, Poland
ENDOMED, s.r.o.
🇸🇰Vranov nad Toplou, Slovakia
Municipal Institution "Kherson City Clinical Hospital n.a. Afanasiy and Olga Tropiny"
🇺🇦Kherson, Ukraine
Municipal Institution "Odesa Regional Clinical Hospital"
🇺🇦Odesa, Ukraine
Ankara Universitesi Tip Fakultesi, Ibn-i-Sina Hastanesi
🇹🇷Ankara, Turkey
Medical University REAVIZ
🇷🇺Samara, Russian Federation
State Budgetary Institution of Healthcare Yaroslavl Regional Clinical Hospital
🇷🇺Yaroslavl, Russian Federation
Ai Centrum Medyczne Sp. Z O.O. Sp.K.
🇵🇱Poznan, Poland
Clinical Centre of Nis, Clinic for Gastroenterology and Hepatology
🇷🇸Nis, Serbia
General Hospital Subotica
🇷🇸Subotica, Serbia
Ankara Universitesi Tip Fakultesi Cebeci Hastanesi
🇹🇷Ankara, Turkey
Bezmialem Vakif Universitesi Tip Fakultesi Hastanesi
🇹🇷Istanbul, Turkey
FGBOU VO OmGMU Minzdrava Rossii
🇷🇺Omsk, Russian Federation
State Budgetary Institution of Ryazan Region "Regional Clinical Hospital"
🇷🇺Ryazan, Russian Federation
Hospital Universitario Puerta de Hierro de Majadahonda
🇪🇸Majadahonda, Madrid, Spain
Istanbul Universitesi Istanbul Tıp Fakultesi
🇹🇷Istanbul, Turkey
Mersin Universitesi Tip Fakultesi Hastanesi
🇹🇷Mersin, Turkey
MNCECCH No.2 n.a. PROF O.O. SHALIMOV of KHARKIV CITY COUNCIL
🇺🇦Kharkiv, Ukraine
Lviv clinical hospital on Railway Transport of Health Care Center branch of PJSC Ukrainian Railway
🇺🇦Lviv, Ukraine
FSBEI HE "Rostov State Medical University" of the Ministry of Healthcare of the Russian Federation
🇷🇺Rostov-on-Don, Russian Federation
Private Healthcare Institution "Clinical Hospital "RZhD-Medicina" City Samara"
🇷🇺Samara, Russian Federation
Clinical Centre of Kragujevac
🇷🇸Kragujevac, Serbia
Abawi spol. s r.o
🇸🇰Bratislava, Slovakia
Istanbul Universitesi Cerrahpasa Tip Fakultesi
🇹🇷Istanbul, Turkey
FSAEI HE I.M.Sechenov 1st Moscow State Medical University of the MoH of the RF (Sechenov University)
🇷🇺Moscow, Russian Federation
Hospital Universitario Marques de Valdecilla
🇪🇸Santander, Cantabria, Spain
Kyiv Municipal Clinical Hospital #18, Proctology Department
🇺🇦Kyiv, Ukraine
Municipal Institution of Ternopil regional council Ternopil University Hospital
🇺🇦Ternopil, Ukraine
Municipal Institution "Uzhgorod Regional Hospital"
🇺🇦Uzhgorod, Ukraine
Zakarpattia Regional Clinical Hospital n.a. A. Novak,
🇺🇦Uzhgorod, Ukraine
Nordsjaellands Hospital Frederikssund
🇩🇰Frederikssund, Denmark
ASST Rhodense - Ospedale di Circolo di Rho
🇮🇹Rho, Milano (MI), Italy
Policlinico Universitario Campus Biomedico
🇮🇹Roma, RM, Italy
AOU Policlinico di Modena
🇮🇹Modena, Italy
Erciyes Universitesi Tip Fakultesi
🇹🇷Kayseri, Turkey
Kocaeli Universitesi Tip Fakultesi
🇹🇷Kocaeli, Turkey
RIAT Limited Liability Company (RIAT LLC)
🇷🇺Saint-Petersburg, Russian Federation
Saint-Petersburg State Budgetary Healthcare Institution
🇷🇺Saint-Petersburg, Russian Federation
LLC Medical Company Hepatolog
🇷🇺Samara, Russian Federation
Hospital Universitari i Politecnic La Fe
🇪🇸Valencia, Spain
Hospital Clinic de Barcelona
🇪🇸Barcelona, Spain
Migdal Hamea Clinic
🇮🇱Tel Aviv, Israel
Tolna Megyei Balassa Janos Korhaz
🇭🇺Szekszard, Hungary
Clinical Application Laboratories, INC.
🇺🇸San Diego, California, United States
Medical Associates Research Group
🇺🇸San Diego, California, United States
Digestive Disease Specialists, Inc.
🇺🇸Oklahoma City, Oklahoma, United States
Sagact, Pllc.
🇺🇸San Antonio, Texas, United States
Sagact, Pllc
🇺🇸San Antonio, Texas, United States
San Diego Endoscopy Center
🇺🇸San Diego, California, United States
Front Range Endoscopy Center
🇺🇸Colorado Springs, Colorado, United States
Connecticut Clinical Research Institute
🇺🇸Bristol, Connecticut, United States
Central Connecticut Endoscopy Center
🇺🇸Plainville, Connecticut, United States
Chevy Chase Endoscopy Center
🇺🇸Chevy Chase, Maryland, United States
MGG Group Co. Inc., Chevy Chase Clinical Research
🇺🇸Chevy Chase, Maryland, United States
Feldman ENT
🇺🇸Chevy Chase, Maryland, United States
Brigham and Women's Hospital
🇺🇸Chestnut Hill, Massachusetts, United States
Concorde medical Group, PLLC
🇺🇸New York, New York, United States
Kips Bay Endoscopy Center
🇺🇸New York, New York, United States
NYU Langone Medical Center
🇺🇸New York, New York, United States
New York University Langone Medical Center
🇺🇸New York, New York, United States
NYU Clinical Cancer Center
🇺🇸New York, New York, United States
Weill Cornell Medical College - New York Presbyterian Hospital
🇺🇸New York, New York, United States
NYU Medical Science Building
🇺🇸New York, New York, United States
New York Presbyterian Hospital-Weill Cornell Medical College
🇺🇸New York, New York, United States
University of Rochester Medical Center
🇺🇸Rochester, New York, United States
Weill Cornell Medical College-New York Presbyterian Hospital
🇺🇸New York, New York, United States
Gastro One
🇺🇸Germantown, Tennessee, United States
Lonestar Endoscopy, LLP
🇺🇸Southlake, Texas, United States
Texas Digestive Disease Consultants
🇺🇸Southlake, Texas, United States
Blue Ridge Medical Research
🇺🇸Lynchburg, Virginia, United States
McGuire DVAMC
🇺🇸Richmond, Virginia, United States
"Medical Center-1- Sevlievo" EOOD
🇧🇬Sevlievo, Gabrovo, Bulgaria
AKH Wien Universitaetsklinik fuer Innere Medizin III
🇦🇹Wien, Austria
MHAT Prof. Dr. Paraskev Stoyanov AD
🇧🇬Lovech, Bulgaria
MC Hipocrat-2000 OOD
🇧🇬Haskovo, Bulgaria
"MC Asklepion - researches in human medicine"" EOOD
🇧🇬Sofia, Bulgaria
"Acibadem City Clinic UMHAT" EOOD
🇧🇬Sofia, Bulgaria
MVZ Dachau
🇩🇪Dachau, Germany
Nemocnice Slany, p.o.
🇨🇿Slany, Czechia
Hepato-Gastroenterologie HK, s.r.o.
🇨🇿Hradec Kralove, Czechia
Nemocnice Strakonice, a.s., interni oddeleni
🇨🇿Strakonice, Czechia
Nordsjaellands Hospital Hilleroed
🇩🇰Hilleroed, Denmark
Research institute of Clinical Medicine
🇬🇪Tbilisi, Georgia
Amager og Hvidovre Hospital
🇩🇰Hvidovre, Denmark
Odense Universitetshospital
🇩🇰Odense, Denmark
Gastrostudien GbR
🇩🇪Berlin, Germany
Krankenhaus Waldfriede e.V.
🇩🇪Berlin, Germany
The First University Clinic of TSMU
🇬🇪Tbilisi, Georgia
Paian MED Research GmbH
🇩🇪Berlin, Germany
MVZ Dachau - Patientenzentrum
🇩🇪Dachau, Germany
Eugastro GmbH
🇩🇪Leipzig, Germany
Asklepios Westklinikum Hamburg
🇩🇪Hamburg, Germany
Bekes Megyei Kozponti Korhaz, Rethy Pal Tagkorhaz
🇭🇺Bekescsaba, Hungary
Azienda Ospedaliera di Padova
🇮🇹Padova, Italy
Azienda Sanitaria Universitaria Integrata Udine
🇮🇹Udine, Italy
Gastromed Sp. z o.o.
🇵🇱Lublin, Poland
Keimyung University Dongsan Hospital
🇰🇷Daegu, Korea, Republic of
EMC Instytut Medyczny S.A., Szpital Specjalistyczny EuroMediCare z Przychodnia
🇵🇱Wroclaw, Poland
LLC "Olla-Med"
🇷🇺Moscow, Russian Federation
S.C. Cabinet Particular Policlinic Algomed SRL
🇷🇴Timisoara, Timis, Romania
Spitalul Universitar de Urgenta Militar Central "Dr. Carol Davila" Bucuresti
🇷🇴Bucuresti, Sector 1,, Romania
Limited Liability Company "Medicinsky Center SibNovoMed"
🇷🇺Novosibirsk, Russian Federation
LLC Novosibirskiy Gastrocentr
🇷🇺Novosibirsk, Russian Federation
Novosibirskiy Gastrocenter
🇷🇺Novosibirsk, Russian Federation
Clinical Hospital Centre Zvezdara Clinic for Internal Diseases
🇷🇸Belgrade, Serbia
Clinical Hospital Center Zemun
🇷🇸Zemun, Belgrade, Serbia
Hospital Universitario Virgen del Rocio
🇪🇸Sevilla, Spain
Bulent Ecevit Universitesi Tip Fakultesi
🇹🇷Zonguldak, Turkey
Medical Center Vitadar Consult OOD
🇧🇬Ruse, Bulgaria
SHATPPD dr. Dimitar Gramatikov - Ruse EOOD
🇧🇬Ruse, Bulgaria
UT Southwestern Medical Center-Clements University Hospital
🇺🇸Dallas, Texas, United States
Universitaetsklinikum Schleswig-Holstein
🇩🇪Kiel, Germany
Peak Gastroenterology Associates
🇺🇸Colorado Springs, Colorado, United States
Centrum Diagnostyczno-Lecznicze Barska Sp. z o. o.
🇵🇱Wloclawek, Poland
Melita Medical Sp z o.o.
🇵🇱Wroclaw, Poland
Centrum Badan Klinicznych, Osrodek Badan Wczesnej Fazy
🇵🇱Wroclaw, Poland
Spitalul Clinic Colentina, Sectia de Gastroenterologie
🇷🇴Bucuresti, Romania
Weill Cornell Medical College
🇺🇸New York, New York, United States
Orlando Gastroenterology, PA
🇺🇸Orlando, Florida, United States
HMD Research LLC
🇺🇸Orlando, Florida, United States
UNC Hospitals Endoscopy Center at Meadowmont
🇺🇸Chapel Hill, North Carolina, United States
University of North Carolina at Chapel Hill
🇺🇸Chapel Hill, North Carolina, United States
Millenia Surgery Center
🇺🇸Orlando, Florida, United States
UNC Hospitals
🇺🇸Chapel Hill, North Carolina, United States